{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Responders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}],"title":"Non-responders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"A responder was assessed as having complete remission (CR) or partial remission (PR). Non-responders had stable disease, progressive disease or were not evaluable.\n\nCR: ≤ 5% myeloblasts with normal maturation of all cell lines and return to normal cellularity; osteomyelofibrosis was absent or equal to mild reticulin fibrosis; resolution of extramedullary disease present before therapy.\n\nPR: normalization of peripheral counts and hepatosplenomegaly with bone marrow blasts reduced by 50% but \\>5% of cellularity except in cases of MDS/MPN with ≤ 5% blasts at baseline.\n\nProgression: ≥ 50% reduction from maximum response levels in granulocytes or platelets, and/or reduction in hemoglobin by ≥ 1.5 g/dL in the absence of another explanation; transfusion dependence.","groups":[{"description":"Participants received IV AMG 176 at dose level 1 once a week in 28-day cycles. Treatment was planned until disease progression or unacceptable toxicity.","id":"OG000","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1"},{"description":"Participants received IV AMG 176 at dose level 1 on cycle 1 day 1 and then dose level 2 from cycle 1 day 8 and once a week thereafter (each cycle = 28 days). Treatment was planned until disease progression or unacceptable toxicity.","id":"OG001","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis set included all enrolled participants who received at least 1 dose of AMG 176.","reportingStatus":"POSTED","timeFrame":"Cycle 1 to disease progression or end of study, whichever occurred earlier (cycle length = 28 days). Median time on study was 4.1 months","title":"Number of Participants With a Response According to the Uniform Response Criteria for MDS/Myeloproliferative Neoplasm (MPN)","type":"SECONDARY","unitOfMeasure":"Participants"}